[A20-90] Filgotinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V

Last updated 15.01.2021

Project no.:
A20-90

Commission:
Commission awarded on 15.10.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Muscles, bones and joints

Indication:

Adults with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more DMARDs

Result of dossier assessment:

First-time therapy with bDMARDs or tsDMARDs indicated: in combination with MTX, hint of minor added benefit. Other constellations: added benefit not proven.

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form